An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease

Core Evidence

Volumn 7, Issue , 2012, Pages 15-20

  Hollak, Carla E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Enzyme replacement therapy; Glucocerebrosidase deficiency; Lysosomal storage disorder; Plant derived recombinant human glucocerebrosidase

Indexed keywords

ALGLUCERASE; ELIGLUSTAT; HEMOGLOBIN; IMIGLUCERASE; MIGLUSTAT; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA;

ABDOMINAL PAIN; ANTIBODY PRODUCTION; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; ENZYME REPLACEMENT; EVIDENCE BASED MEDICINE; GAUCHER DISEASE; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE COUNT;

EID: 84867369035     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S20201     Document Type: Review

References (20)

1. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. Vol 3. 8th ed. New York, NY: McGraw-Hill; 2001:3635-3668.
2. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324(21):1464-1470.
3. Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115(23):4651-4656.
4. Opar A. 'Pharmers' hope for first plant drug harvest. Nat Rev Drug Discov. 2011;10(2):81-82.
5. Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007;5(5):579-590. (Pubitemid 47196361)
6. Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology. 2009;20(1):24-32.
7. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767-5773.
8. Pastores G, Fernhoff P, Jeffrey S, et al. Plant cell expressed recombinant glucocerebrosidase - taliglucerase alfa - as therapy for Gaucher disease in patients previously treated with imiglucerase [meeting abstract]. Mol Genet Metab, Volume 105, Issue 2, February 2012, Page S50.
9. Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme: a preclinical and phase I investigation. PLoS One. 2009;4(3):e4792.
10. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest. 1994;93(3):1288-1292.
11. Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol. 2007;138(6):676-686. (Pubitemid 47313204)
12. Zimran A, Heitner R, Mehta A, et al. Long term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in treatment of naïve Gaucher disease patients. Mol Genet Metab. 2012;105(2):S68
13. Protalix announces new clinical data on taliglucerase alfa to be presented at the WORLD lysosomal disease network symposium [press release]. Karmiel, Israel: Protalix Biotherapeutics; February 9, 2012. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irolnewsArticle&ID= 1658750&highlight/. Accessed March 8,2012.
14. Personal communication Dr. E Almon, 2012.
15. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol. 2002;179(4):961-965.
16. Van Dussen L, Hollak CEM, Zimran A, et al. Long term bone marrow responses, as measured by Quantitative Chemical Shift Imaging (QCSI) MRI, following treatment with taliglucerase alfa in patients with type 1 Gaucher disease. Mol Genet Metab. 2012;105(2):S62-S63.
17. Hollak CE, vom Dahl S, Aerts JM, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44(1):41-47.
18. Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513-526. (Pubitemid 37321530)
19. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095-4098.
20. Hollak CE, Aerts JM, Aymé S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis. 2011;6:16.